Obesity in Expectant Mothers May Hinder Development of Babies’ Brains As Early as the Second Trimester According to a New Study

Obesity in Expectant Mothers Study was led by researchers at NYU Grossman School of Medicine. The investigation linked high body mass index (BMI), an indicator of obesity, to changes in two brain areas, the prefrontal cortex and anterior insula. These regions play a key role in decision-making and behavior, with disruptions having previously been linked to attention-deficit/hyperactivity disorder (ADHD), autism, and overeating.

In their new study, publishing online August 11 in the Journal of Child Psychology and Psychiatry, the investigators examined 197 groups of metabolically active nerve cells in the fetal brain. Using millions of computations, the study authors divided the groups into 16 meaningful subgroups based on over 19,000 possible connections between the groups of neurons. They found only two areas of the brain where their connections to each other were statistically strongly linked to the mother’s BMI.

“Our findings affirm that a mother’s obesity may play a role in fetal brain development, which might explain some of the cognitive and metabolic health concerns seen in children born to mothers with higher BMI,” says Moriah Thomason, PhD, the Barakett Associate Professor in the Department of Child and Adolescent Psychiatry at NYU Langone Health.

As obesity rates continue to soar in the United States, it is more important than ever to understand how the condition may impact early brain development, says Thomason, who is also an associate professor in the Department of Population Health at NYU Langone.

Previous studies showing an association between obesity and brain development had mostly looked at cognitive function in children after birth. The new investigation is believed to be the first to measure changes in fetal brain activity in the womb, and as early as six months into pregnancy.

Thomason says this approach was designed to eliminate the potential influence of breast feeding and other environmental factors occurring after birth and to examine the earliest origins of negative effects of maternal BMI on the developing child’s brain.

For the investigation, the research team recruited 109 women with BMIs ranging from 25 to 47. (According to the National Institutes of Health, women are considered “overweight” if they have a BMI of 25 or higher and are “obese” if their BMI is 30 and higher.) The women were all between six and nine months’ pregnant.

The research team used MRI imaging to measure fetal brain activity and map patterns of communication between large numbers of brain cells clustered together in different regions of the brain. Then, they compared the study participants to identify differences in how groups of neurons communicate with each other based on BMI.

The investigators caution that their study was not designed to draw a direct line between the differences they found and ultimate cognitive or behavioral problems in children. The study only looked at fetal brain activity. But, Thomason says, they now plan to follow the participants’ children over time to determine whether the brain activity changes lead to ADHD, behavioral issues, and other health risks.

Funding for the study was provided by National Institutes of Health grants R01 MH110793, R34 DA050287, R01 MH122447, and R21 ES026022.

In addition to Thomason, other NYU researchers involved in the study included Carly Lenniger, BS. Megan Norr, BA, of the University of California Berkeley, served as the study lead author. Additional research support was provided by Jasmine Hect, BS, of Wayne State University in Detroit, Michigan, and Martijn van den Heuvel of VU University Medical Center in Amsterdam, the Netherlands.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version